Good afternoon, everyone, and welcome to the Stocktwits Top 25 Newsletter for Week 48, 2020.
The Stocktwits Top 25 reports the top 25 performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here’s your Stocktwits Top 25 Lists for Week 48:
ST Top 25 S&P 500
The ST Top 25 S&P 500 was strong once again. Winners overwhelmed Sinners 17 to 8.
ETSY was the standout as it gained 14.5% and reclaimed the #1 spot on the ST Top 25. See more below.
Freeport-McMoRan nearly doubled its ranking, moving from #20 to #11. $FCX gained 10.68% and closed at levels not seen since 2015.
#13 Catalent was the worst performing stock on the ST Top 25 S&P 500 list. $CTLT fell 5.75% and dropped 6 spots from #13 to #7.
The Stocktwits Top 25 S&P 500 Momentum Meter gained 2.44% while the S&P 500 rose 2.27%. The differential of 0.17% indicates that the top stocks in the S&P 500 slightly outperformed the full index.
The Big Cap Nasdaq 100
It took another stellar week from $TSLA to snatch the top spot from $ZM as the leader of the ST Top 25 N100 List. Tesla posted back-to-back 19% weeks and stole the crown. It’s a winner below.
#22 Seagen was this week’s biggest loser, down 2.5%. It dropped in back-to-back weeks.
Autodesk’s 7% weekly gain was enough to grab the #21 spot and be named a Winner. The software company was the list’s only Freshman, see more below.
The ST Top 25 Nasdaq 100 Momentum Meter gained 3.39% for Week #48 while the full Nasdaq 100 jumped 2.95%. The 0.44% differential suggests the index outperformed by a slim margin.
Small-Cap Russell 2000
The ST Top 25 Russell 2000 List never ceases to amaze. 15 names closed higher in an eventful week.
Top ranked stock, Novavax, ascended 45% in dominant fashion. The biotech now sits over 1,000% ahead of Vaxart.
#11 Seres Therapeutics was the worst performing stock. The laggard tumbled 16%, read more below.
Appian Corporation came to life this week, soaring 55%. It is one of six Freshmen on the ST Top 25 R2K List and is Week 48’s Top Dawg.
The ST Top 25 R2K Momentum Meter ripped 7.29% while the Russell 2000 index closed up 3.92%. The 3.37% differential suggests that the top stocks were much stronger than the full index.
ST Top 25 TOP DAWG OF THE WEEK 🐶
The ST Top 25 Top Dawg for Week 48, 2020 is #24 R2K – Appian Corporation.
$APPN claimed the #24 spot on the ST Top 25 R2K List and the Top Dawg title thanks to a blowout performance, up 55% this week. The Freshman flew +200% in November alone. 💪
Here’s November’s week-by-week performance:
Week of Nov. 2 +43%
Week of Nov. 9 +10%
Week of Nov. 16 +26%
Week of Nov. 23 +55%
Appian is the leading provider of low-code automation solutions for government and defense organizations began its impressive November advance following its Q3 earnings beat on 11/05/2020. Cloud subscription revenue grew 40% YoY.
$APPN will host its 4th annual AppianGOVERNMENT event on December 8th to explore the expanding role of low-code automation in service and program delivery. Stay tuned to see if the company has more room for growth 📈
Here’s the weekly chart:
$APPN is up 407% YTD.
The Winners 📈
△ #1 R2K – Novavax was green all 4 days this week. The stock vaulted 22.5% higher during Friday’s session on news that competitor AstraZeneca and partner Oxford University are expected to run another late-stage trial for their Covid-19 vaccine candidate.
Here’s an excerpt from Pierre Briancon, a European man who has already taken Novavax’s COVID vaccine twice:
I just received my second shot a few days ago. The answers to all of my friends’ questions are negative. No, I never considered it was risky. No, of course I’m not getting paid. And, as all the experts would tell you, it does make very much sense for Novavax and the dozens of other vaccine candidates to continue with the trials — even if three other vaccines have already shown results, something that was not expected to happen so fast when the world was confronted earlier this year with the calamity of the first coronavirus wave…
So I still root for Novavax, which will take another few months to tell us about the trial result, and just extended its pool of volunteers in the U.K. from 10,000 to 15,000 — even though I may not even be vaccinated at all: Half of us were injected with a placebo, an inactive saline solution looking like a vaccine dose that will have no effect on our immune system. This is a “double blind” trial where even the doctors and nurses following us do not know whether we got the vaccine.
Here’s the full story.
And the YTD chart, up 3,058% YTD.
△ #1 S&P 500 – Etsy had itself a week. Not only did the e-commerce company close at all-time highs, it also re-took the #1 spot on the ST Top 25 S&P 500 List from Carrier Group.
$ETSY began the week trading quietly, until it found its mojo Wednesday, gaining 5.5%. The name must’ve had its fixing of Turkey on Thanksgiving because it leapt out of the gate Friday to close up 10.5%. 🦃
Here’s the weekly chart:
△ #21 N100 – Autodesk, Inc notched 4 green days in Week 48 to gain 7%. The software company released Q3 earnings on Tuesday and the stock took off. $ADSK was the ST Top 25 N100 List’s only Freshman.
$ADSK reported an earnings increase of 33% YoY along with revenue rising 13% in the same period. Here’s the press release.
Andrew Anagnost, Autodesk CEO said:
Our strong third quarter results reflect the growing customer value of our cloud-based platform and the resilience of our subscription business model. Our enterprise customers are undertaking their own digital transformation and, by enabling that transformation, we are becoming strategic partners. For example, we signed a nine-digit deal in the quarter. We are confident in our fiscal 2023 targets and expect to see continued double-digit growth thereafter.
$ADSK is now trading at all-time highs.
△ #1 N100 – Tesla, Inc posted another 20% weekly gain because, why not. 🤷 The stock closed green everyday this week, a common theme among Week 48’s Winners.
For the first time since the ST Top 25 N100 List’s inception in Week #23, Zoom Video is not the top ranked stock. It was a long time coming but we wouldn’t have it any other way. Congrats, $TSLA.
$TSLA is now up over 40% since the announcement dropped that the company will be added to the S&P 500 Index. Winners win.
Here’s the daily chart.
The Sinners 📉
▼ #13 S&P 500 – Catalent, Inc fell 5.74% and lost 6 spots on the ST Top 25 N100 List. It ranks #13.
Things haven’t been the same for $CTLT since it faded the quarterly earnings report on Nov. 9, now down 20% from the gap-up.
Here’s the daily chart with the big red ugly candle:
▼ #11 R2K– Seres Therapeutics, Inc dropped 16% last week and slipped 4 spots from #7 to #11. It was the worst performer out of all three lists. The stock is still up 741% YTD.
$MCRB fell just 1% Monday but set the tone for what would become a poor week. It tumbled 10% Tuesday and another 4% Wednesday.
Seres Therapeutics will participate in two upcoming investor conferences:
- Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020. A fireside chat held with Seres management will be made available on the News and Events section of the Company’s website on November 23, 2020.
- 3rd Annual Evercore ISI HealthCONx Virtual Conference on December 2, 2020. Management will participate in 1×1 meetings.
See Y’all Next Week
